Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as...
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. Specifically, the stock is fairly valued on P/E, undervalued on EV/EBITDA,
Target Price
The average target price of IRWD is 4.5 and suggests 2% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation su
Buy
Sell